Kobo Biotech Limited (BOM:531541)
India
· Delayed Price · Currency is INR 2.360
+0.030 (1.29%)
At close: Mar 9, 2026
Kobo Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Cost of Revenue | - | - | - | 352.38 | - | 0 | Upgrade
|
| Gross Profit | - | - | - | -352.38 | - | -0 | Upgrade
|
| Selling, General & Admin | 2.58 | 2.48 | 2.3 | 7.15 | 13.93 | 17.96 | Upgrade
|
| Other Operating Expenses | 7.29 | 6.25 | 7.16 | -958.36 | 8.13 | 8.11 | Upgrade
|
| Operating Expenses | 50.57 | 49.44 | 50.18 | -173.59 | 78.43 | 84.86 | Upgrade
|
| Operating Income | -50.57 | -49.44 | -50.18 | -178.79 | -78.43 | -84.86 | Upgrade
|
| Interest Expense | -0 | -0 | - | -1.34 | -108 | -144 | Upgrade
|
| Interest & Investment Income | - | - | 0.15 | 0.17 | 0.36 | 0.34 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | -5.51 | -89.62 | -5.83 | 19.2 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.24 | 0.15 | -0 | -0 | -0.41 | -0.75 | Upgrade
|
| EBT Excluding Unusual Items | -50.33 | -49.29 | -55.53 | -269.6 | -192.31 | -210.06 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -121.93 | - | - | Upgrade
|
| Asset Writedown | - | - | - | -128.92 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 368.19 | - | - | Upgrade
|
| Pretax Income | -50.33 | -49.29 | -55.53 | -152.26 | -192.31 | -210.06 | Upgrade
|
| Net Income | -50.33 | -49.29 | -55.53 | -152.26 | -192.31 | -210.06 | Upgrade
|
| Net Income to Common | -50.33 | -49.29 | -55.53 | -152.26 | -192.31 | -210.06 | Upgrade
|
| Shares Outstanding (Basic) | 24 | 24 | 24 | 24 | 24 | 24 | Upgrade
|
| Shares Outstanding (Diluted) | 24 | 24 | 24 | 24 | 24 | 24 | Upgrade
|
| Shares Change (YoY) | -0.80% | -0.06% | - | - | 0.04% | - | Upgrade
|
| EPS (Basic) | -2.12 | -2.07 | -2.33 | -6.39 | -8.07 | -8.82 | Upgrade
|
| EPS (Diluted) | -2.12 | -2.07 | -2.33 | -6.39 | -8.07 | -8.82 | Upgrade
|
| Free Cash Flow | - | 2.04 | 8.75 | 937.57 | 25.09 | 144.73 | Upgrade
|
| Free Cash Flow Per Share | - | 0.09 | 0.37 | 39.35 | 1.05 | 6.08 | Upgrade
|
| EBITDA | -9.83 | -8.73 | -9.54 | -134.47 | -22.06 | -26.08 | Upgrade
|
| D&A For EBITDA | 40.73 | 40.71 | 40.64 | 44.32 | 56.37 | 58.78 | Upgrade
|
| EBIT | -50.57 | -49.44 | -50.18 | -178.79 | -78.43 | -84.86 | Upgrade
|
| Revenue as Reported | 0.24 | 0.15 | 0.15 | 0.17 | 0.36 | 0.34 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.